Heart Valve Devices – Market Insights – United States

The US heart valve device market has seen rapid shifts in market dynamics, from renewed growth in the surgical heart valve device segment to the introduction of novel products and key approvals of existing products for new indications. In particular, recent approvals of transcatheter tricuspid therapies will support growth in coming years. The market continues to grow more competitive as more players enter the space and engage in mergers and acquisitions.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for heart valve devices in the US from 2019 through 2033.

Clinical trial results play an important factor in the heart valve device market.

Which segments have been the most impacted by clinical results?

Which key players will have a first-mover advantage if they can secure positive clinical trial results?

Which novel devices have been approved or have failed to gain approval due to data from clinical trials?

How have recent clinical trial results impacted confidence in particular device types and how will this affect procedure trends?

Securing approval for additional indications and CMS reimbursement are key strategies in the THV device market.

Which THV device segments are being driven by the approval of additional indications?

Which competitors are capitalizing on approvals for additional indications to gain a competitive advantage?

Which newly-approved THV devices are expected to receive approval for a CMS reimbursement scheme in the near future?

Recent FDA approvals for transcatheter tricuspid valve devices will serve a large unmet need.

How will recent approvals in the TTVI and TTVR device segments impact the market?

What are the key differences between these types of devices and what are their respective growth outlooks?

The competitive landscape for the THV device market is evolving.

Which competitors have the most diverse portfolios in the heart valve device space?

What market dynamics will occur between TMVI and TMVR devices?

Which companies are poised to earn FDA approval for their THV devices first?

What impact will these devices have once approved?

Recent market developments and events have a significant impact on the heart valve device market.

What effect have mergers and acquisitions had on this market?

How will innovations currently being developed and evaluated in clinical trials affect changes in market share dynamics?

How has the preference for transcatheter and surgical valve treatment shifted with recent clinical results and market conditions?